BIODESIX INC (BDSX) Fundamental Analysis & Valuation

NASDAQ:BDSX • US09075X2071

Current stock price

10.64 USD
+0.68 (+6.83%)
Last:

This BDSX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. BDSX Profitability Analysis

1.1 Basic Checks

  • In the past year BDSX has reported negative net income.
  • In the past year BDSX has reported a negative cash flow from operations.
  • In the past 5 years BDSX always reported negative net income.
  • BDSX had a negative operating cash flow in each of the past 5 years.
BDSX Yearly Net Income VS EBIT VS OCF VS FCFBDSX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • BDSX has a Return On Assets of -40.31%. This is amonst the worse of the industry: BDSX underperforms 85.00% of its industry peers.
Industry RankSector Rank
ROA -40.31%
ROE N/A
ROIC N/A
ROA(3y)-45.69%
ROA(5y)-52.85%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BDSX Yearly ROA, ROE, ROICBDSX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K -1K

1.3 Margins

  • BDSX has a better Gross Margin (81.11%) than 96.00% of its industry peers.
  • BDSX's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for BDSX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 81.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.81%
GM growth 5Y9.42%
BDSX Yearly Profit, Operating, Gross MarginsBDSX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. BDSX Health Analysis

2.1 Basic Checks

  • BDSX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, BDSX has more shares outstanding
  • The number of shares outstanding for BDSX has been increased compared to 5 years ago.
  • The debt/assets ratio for BDSX is higher compared to a year ago.
BDSX Yearly Shares OutstandingBDSX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
BDSX Yearly Total Debt VS Total AssetsBDSX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -7.12, we must say that BDSX is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -7.12, BDSX is not doing good in the industry: 87.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.12
ROIC/WACCN/A
WACC10.83%
BDSX Yearly LT Debt VS Equity VS FCFBDSX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M

2.3 Liquidity

  • A Current Ratio of 1.86 indicates that BDSX should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.86, BDSX is in the better half of the industry, outperforming 76.00% of the companies in the same industry.
  • BDSX has a Quick Ratio of 1.86. This is a normal value and indicates that BDSX is financially healthy and should not expect problems in meeting its short term obligations.
  • BDSX has a better Quick ratio (1.86) than 79.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.86
Quick Ratio 1.86
BDSX Yearly Current Assets VS Current LiabilitesBDSX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. BDSX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 30.71% over the past year.
  • Looking at the last year, BDSX shows a very strong growth in Revenue. The Revenue has grown by 24.08%.
  • BDSX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.20% yearly.
EPS 1Y (TTM)30.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.17%
Revenue 1Y (TTM)24.08%
Revenue growth 3Y32.31%
Revenue growth 5Y14.2%
Sales Q2Q%23.1%

3.2 Future

  • BDSX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.82% yearly.
  • BDSX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.25% yearly.
EPS Next Y35.35%
EPS Next 2Y26.12%
EPS Next 3Y19.82%
EPS Next 5YN/A
Revenue Next Year27.38%
Revenue Next 2Y23.2%
Revenue Next 3Y21.25%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BDSX Yearly Revenue VS EstimatesBDSX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M
BDSX Yearly EPS VS EstimatesBDSX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

0

4. BDSX Valuation Analysis

4.1 Price/Earnings Ratio

  • BDSX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year BDSX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BDSX Price Earnings VS Forward Price EarningsBDSX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BDSX Per share dataBDSX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

  • BDSX's earnings are expected to grow with 19.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.12%
EPS Next 3Y19.82%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BDSX Dividend Analysis

5.1 Amount

  • No dividends for BDSX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BDSX Fundamentals: All Metrics, Ratios and Statistics

BIODESIX INC

NASDAQ:BDSX (4/24/2026, 4:30:02 PM)

10.64

+0.68 (+6.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-26
Earnings (Next)05-11
Inst Owners21.53%
Inst Owner Change0.88%
Ins Owners19.56%
Ins Owner Change0.62%
Market Cap107.57M
Revenue(TTM)88.50M
Net Income(TTM)-35.27M
Analysts83.64
Price Target30.6 (187.59%)
Short Float %3.38%
Short Ratio1.51
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.42%
Min EPS beat(2)21.02%
Max EPS beat(2)43.81%
EPS beat(4)2
Avg EPS beat(4)8.68%
Min EPS beat(4)-15.34%
Max EPS beat(4)43.81%
EPS beat(8)6
Avg EPS beat(8)8.99%
EPS beat(12)10
Avg EPS beat(12)9.27%
EPS beat(16)11
Avg EPS beat(16)4.99%
Revenue beat(2)1
Avg Revenue beat(2)-1.21%
Min Revenue beat(2)-4.17%
Max Revenue beat(2)1.75%
Revenue beat(4)2
Avg Revenue beat(4)-1.42%
Min Revenue beat(4)-9.55%
Max Revenue beat(4)6.29%
Revenue beat(8)5
Avg Revenue beat(8)0.19%
Revenue beat(12)6
Avg Revenue beat(12)-1.06%
Revenue beat(16)8
Avg Revenue beat(16)0.19%
PT rev (1m)-7.69%
PT rev (3m)-7.69%
EPS NQ rev (1m)-1.86%
EPS NQ rev (3m)-3.89%
EPS NY rev (1m)6.85%
EPS NY rev (3m)2.84%
Revenue NQ rev (1m)0.7%
Revenue NQ rev (3m)-2.21%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.22
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.85
EYN/A
EPS(NY)-3.14
Fwd EYN/A
FCF(TTM)-2.34
FCFYN/A
OCF(TTM)-2.3
OCFYN/A
SpS8.75
BVpS-0.24
TBVpS-2.11
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -40.31%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 81.11%
FCFM N/A
ROA(3y)-45.69%
ROA(5y)-52.85%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.81%
GM growth 5Y9.42%
F-Score4
Asset Turnover1.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.11%
Cap/Sales 0.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.86
Quick Ratio 1.86
Altman-Z -7.12
F-Score4
WACC10.83%
ROIC/WACCN/A
Cap/Depr(3y)253.22%
Cap/Depr(5y)187.58%
Cap/Sales(3y)17.42%
Cap/Sales(5y)13.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.17%
EPS Next Y35.35%
EPS Next 2Y26.12%
EPS Next 3Y19.82%
EPS Next 5YN/A
Revenue 1Y (TTM)24.08%
Revenue growth 3Y32.31%
Revenue growth 5Y14.2%
Sales Q2Q%23.1%
Revenue Next Year27.38%
Revenue Next 2Y23.2%
Revenue Next 3Y21.25%
Revenue Next 5YN/A
EBIT growth 1Y18.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year74.32%
EBIT Next 3Y34.88%
EBIT Next 5YN/A
FCF growth 1Y54.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.17%
OCF growth 3YN/A
OCF growth 5YN/A

BIODESIX INC / BDSX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIODESIX INC?

ChartMill assigns a fundamental rating of 2 / 10 to BDSX.


What is the valuation status of BIODESIX INC (BDSX) stock?

ChartMill assigns a valuation rating of 0 / 10 to BIODESIX INC (BDSX). This can be considered as Overvalued.


What is the profitability of BDSX stock?

BIODESIX INC (BDSX) has a profitability rating of 1 / 10.


What is the earnings growth outlook for BIODESIX INC?

The Earnings per Share (EPS) of BIODESIX INC (BDSX) is expected to grow by 35.35% in the next year.